pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
the cabinet

Drugs

8,127 products tracked

★ save view↓export CSV
phase
allMarketedPhase 3Phase 2Phase 1Preclinical
sort
catalystsrecentname
therapeutic area
allOncology1831Infectious Disease718Cardiology425Pulmonology396Immunology371Ophthalmology368Dermatology300Women's Health
viewlistcards
BEYFORTUS
BEYFORTUS (NIRSEVIMAB-ALIP)
1 INDICATIONS AND USAGE BEYFORTUS is indicated for the prevention of Respirat…
Fusion glycoprotein F0
$AZNASTRAZENECA PLC
0 catalysts
Preclinical
BF-844
Usher Syndrome
Case Western Reserve University
0 catalysts
Preclinical
BG-22
Solid Tumor
BioStar Pharmaceuticals Inc
0 catalysts
Preclinical
← prev
page 66 of 271
next →
131
Pain89
Neurology1
BG-319
Type 1 Diabetes (Juvenile Diabetes)
Bioorg3.14 LLC
0 catalysts
Preclinical
BGA-002
Small-Cell Lung Cancer
Biogenera SpA
0 catalysts
Phase 2
BGB-16673
Refractory Chronic Lymphocytic Leukemia (CLL)
$ONCBeOne Medicines Ltd.
0 catalysts
Phase 1
BGBB-2033
Metastatic Hepatocellular Carcinoma (HCC)
$ONCBeOne Medicines Ltd.
0 catalysts
Phase 2
BGC-101
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)
BiogenCell Ltd
0 catalysts
Phase 1
BGC-515
Malignant Mesothelioma
BridGene Biosciences Inc
0 catalysts
Preclinical
BGI-9004
Malignant Mesothelioma
BridGene Biosciences Inc
0 catalysts
Phase 1
BGM-1812
Obesity
BrightGene Bio-Medical Technology Co Ltd
0 catalysts
Preclinical
BGT-DTDS
Neurology
Bloomsbury Genetic Therapies Ltd
0 catalysts
Preclinical
BGT-INAD
Neurodegenerative Diseases
Bloomsbury Genetic Therapies Ltd
0 catalysts
Preclinical
BGT-NPC
Niemann-Pick Disease Type C
Bloomsbury Genetic Therapies Ltd
0 catalysts
Preclinical
BGTF-027
Achromatopsia
Blue Gen Therapeutics Foundation
0 catalysts
Phase 1
BH-30236
Refractory Acute Myeloid Leukemia
BlossomHill Therapeutics Inc
0 catalysts
Phase 1
BH-3120
Solid Tumor
Hanmi Pharmaceuticals Co Ltd
0 catalysts
Phase 2
BHV-1510
Solid Tumor
$BHVNBiohaven Ltd.
0 catalysts
Phase 1
BHV-1530
Glioblastoma Multiforme (GBM)
$BHVNBiohaven Ltd.
0 catalysts
Phase 2
BI-1206
B-Cell Non-Hodgkin Lymphoma
BioInvent International AB
0 catalysts
Phase 2
BI-1808
Mycosis Fungoides
BioInvent International AB
0 catalysts
Phase 2
BI-1819479
Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim International GmbH
0 catalysts
Phase 2
BI-836858
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Boehringer Ingelheim International GmbH
0 catalysts
Preclinical
BICX-101 SR
naltrexone hydrochloride
Alcohol Use Disorder (AUD)
$BICXBioCorRx Inc.
0 catalysts
Preclinical
BICX-102
naltrexone hydrochloride
Alcohol Use Disorder (AUD)
$BICXBioCorRx Inc.
0 catalysts
BIDIL
BIDIL (HYDRALAZINE HYDROCHLORIDE AND ISOSORBIDE DINITRATE)
AZURITY
0 catalysts
Phase 1
BIIB-142
Lupus Nephritis
$BIIBBIOGEN INC.
0 catalysts
BIJUVA
BIJUVA (ESTRADIOL)
Mayne Pharma Group Ltd
0 catalysts
Phase 2
BIMATOPROST
BIMATOPROST (BIMATOPROST)
1 INDICATIONS AND USAGE Bimatoprost ophthalmic solution 0.03% is indicated fo…
Prostaglandin F2-alpha receptor
$AMRXAmneal Pharmaceuticals, Inc.
0 catalysts
Phase 2
BIO-106
Solid Tumor
BiOneCure Therapeutics Inc
0 catalysts